Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Seagen Inc.
Takeda
Tempus AI
Novartis
NGM Biopharmaceuticals, Inc
Elevation Oncology
MacroGenics
Pfizer
TopAlliance Biosciences
Merck Sharp & Dohme LLC
BioNTech SE
Janssen Pharmaceutical K.K.
Adaptimmune
ADC Therapeutics S.A.
Five Prime Therapeutics, Inc.
Jiangsu HengRui Medicine Co., Ltd.
pharmaand GmbH
Merck Sharp & Dohme LLC
Genmab
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Incyte Corporation
Merck Sharp & Dohme LLC
Ono Pharmaceutical Co. Ltd
Boston Scientific Corporation
Pentax Medical
Organon and Co
Seagen Inc.
Seagen Inc.
Gilead Sciences
Seagen Inc.
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany
Merit Medical Systems, Inc.
Merrimack Pharmaceuticals
Amgen
CSA Medical, Inc.
Eli Lilly and Company
Amgen
INSYS Therapeutics Inc
Bristol-Myers Squibb
Altor BioScience
GlaxoSmithKline